Real-World Usage of Teneligliptin in Indian Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Multicenter Study

Read full text Summarise with VIRAT
Authors: Jayesh Biyani, Ashwin Subramaniam, Kunta Kishore Babu, Supratik Bhattacharya, Manoranjan Tripathy, Sumit Bhushan, Sanjay Chaudhari, Rahee Borulkar, Prajakta Bhosale, Rujuta Gadkari, Saiprasad Patil
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Type 2 diabetes mellitus (T2DM) represents a major public health challenge globally and in India.Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely recommended for glycemic management due to their favorable safety profile and low risk of hypoglycemia.Teneligliptin, a novel DPP-4 inhibitor, has gained widespread use in India; however, real-world data describing its prescribing patterns and patient characteristics remain limited.This study aimed to evaluate the clinical utilization of Teneligliptin in Indian patients with T2DM.Methods: This retrospective, cross-sectional, multicenter, noninterventional study analyzed medical records of adult patients with T2DM who were prescribed Teneligliptin (10 or 20 mg once daily) across 64 healthcare centers in India between September 2024 and March 2025.Descriptive statistics were used to summarize the data.Results: A total of 624 patients with T2DM were included.The mean age was 52.13 ± 11.11 years, with a male predominance (67.14%).Teneligliptin was initiated as first-line therapy in 45.19% of treatment-naïve patients, while 49.20% were switched from previous antidiabetic regimens, most commonly sulfonylurea-or metformin-based therapies.Addon therapy was observed in 21.63% of patients.At initiation, the mean fasting blood glucose, postprandial glucose, and HbA1c were 167.42 ± 48.54 mg/dL, 236.77 ± 62.92 mg/dL, and 7.96 ± 0.94%, respectively.Hypertension (33.33%), obesity (25.32%), and dyslipidemia (18.75%) were the most common comorbidities.Conclusion: This study demonstrates the widespread use of Teneligliptin in India as initial, add-on, or switch therapy in T2DM management.The findings highlight its integration into routine clinical practice, particularly in patients with multiple comorbidities, providing valuable practice-based evidence to inform diabetes management strategies.

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Management and Research Diabetes Cardiovascular Risks and Lipoproteins

Publication details

Journal / source
Current Trends in Internal Medicine
Volume
10
Issue
1
Publication date
25 March 2026
Language
EN